2026 San Francisco Lung Cancer Conference

08:05 AM - 08:20 AM

Application of Targeted Therapy in early stage NSCLC – Collin Blakely, MD

08:20 AM - 08:35 AM

Optimal Sequencing of Therapy in EGFR Mutant NSCLC – Deepti Behl, MD

08:35 AM - 08:50 AM

Targeting HER2 in NSCLC – Nathaniel James Myall, MD

08:50 AM - 09:05 AM

EGFR Exon 20 ins & Uncommon Mutations in NSCLC – Sid Devarakonda, MD

09:05 AM - 09:20 AM

Targeting Other Uncommon Oncogene Drivers – Mohana Roy, MD

09:20 AM - 09:35 AM

Case Discussion – Jacqueline Aredo, MD

09:35 AM - 09:50 AM

Evolution of ALK and ROS1 Treatments in Lung Cancer – Tianhong Li, MD, PhD

09:50 AM - 10:05 AM

Next Generation KRAS Inhibitors – Robert Chun-Hao Hsu, MD

10:05 AM - 10:20 AM

Case Discussion – Tyiesha Brown, MD

11:05 AM - 11:20 AM

Early stage immunotherapy – Dron Gauchan, MD

11:20 AM - 11:35 AM

New Biomarkers & Role of MRD – Arta M Monjazeb, MD, PhD

11:35 AM - 11:50 AM

ADCs in Lung Cancer – Kim-son Nguyen, MD

11:50 AM - 12:05 PM

Novel IO Agents in NSCLC – Greg Allen

12:05 PM - 12:20 PM

Case Discussion – Kevin Lu, MD; Sterling Humphrey, MD

02:20 PM - 02:35 PM

Advances in SCLC – Millie Das, MD

02:35 PM - 02:50 PM

Treatment of Thymic Malignancies & Mesothelioma – Matthew Gubens, MD

02:50 PM - 03:05 PM

New Targets in Squamous NSCLC – Shiruyeh Schokrpur, MD, PhD

03:05 PM - 03:20 PM

Case Discussion – Ryan Quinton, MD, PhD